Jirapongsananuruk O, Leung D Y
Department of Paediatrics, National Jewish Medical and Research Center,Denver, CO 80206, USA.
Clin Exp Immunol. 1999 Oct;118(1):1-8. doi: 10.1046/j.1365-2249.1999.01028.x.
Several recent studies demonstrate that B7.2, but not B7.1, play an important role in allergic inflammation and IgE production. Agents that down-regulate B7.2 may therefore be of benefit for the treatment of Th2-driven allergic diseases. Our current study was carried out to investigate the effect of immunosuppressive agents, cyclosporin A (CsA) and dexamethasone, on B7.2 and B7.1 expression on B cells stimulated with the superantigen, toxic shock syndrome toxin-1 (TSST-1). The analysis of B7.2 and B7.1 on the same cells by flow cytometry demonstrated that TSST-1 up-regulated B7.2+B7.1- but not B7.1+B7.2- on B cells in a dose-dependent fashion. CsA and dexamethasone significantly down-regulated B7.2+B7.1- but up-regulated B7.2-B7.1+ B cells in the presence or absence of TSST-1 (100 ng/ml). Interestingly, the combination of CsA and dexamethasone was much more potent in the inhibition of B7.2 expression than either of these agents alone. As CD40 is known to up-regulate B7.2 expression on B cells, the mechanism of B7.2 down-regulation by CsA and dexamethasone was further studied by investigating the effect of these agents on CD40 expression on B cells. TSST-1 significantly increased CD40 expression on B cells. However, the addition of CsA or dexamethasone significantly down-regulated CD40 expression. Anti-CD40 MoAb significantly reversed the effects of CsA or dexamethasone on B7.2 and B7.1 expression, suggesting that T cell engagement of CD40 plays a role in the mechanisms by which CsA and dexamethasone acts on B cells. These data demonstrate the modulatory effect of CsA and dexamethasone on B7.2 and B7.1 expression on B cells and the potential role of CD40 in mediating this effect.
最近的几项研究表明,在变应性炎症和IgE产生中起重要作用的是B7.2而非B7.1。因此,下调B7.2的药物可能对治疗Th2驱动的变应性疾病有益。我们目前的研究旨在调查免疫抑制剂环孢素A(CsA)和地塞米松对用超抗原中毒性休克综合征毒素-1(TSST-1)刺激的B细胞上B7.2和B7.1表达的影响。通过流式细胞术对同一细胞上的B7.2和B7.1进行分析表明,TSST-1以剂量依赖方式上调B细胞上的B7.2+B7.1-而非B7.1+B7.2-。在存在或不存在TSST-1(100 ng/ml)的情况下,CsA和地塞米松显著下调B7.2+B7.1-但上调B7.2-B7.1+ B细胞。有趣的是,CsA和地塞米松联合使用在抑制B7.2表达方面比单独使用这两种药物中的任何一种都更有效。由于已知CD40可上调B细胞上的B7.2表达,通过研究这些药物对B细胞上CD40表达的影响,进一步研究了CsA和地塞米松下调B7.2的机制。TSST-1显著增加B细胞上的CD40表达。然而,添加CsA或地塞米松显著下调CD40表达。抗CD40单克隆抗体显著逆转了CsA或地塞米松对B7.2和B7.1表达的影响,表明CD40的T细胞结合在CsA和地塞米松作用于B细胞的机制中起作用。这些数据证明了CsA和地塞米松对B细胞上B7.2和B7.1表达的调节作用以及CD40在介导这种作用中的潜在作用。